Read Why Aeglea BioTherapeutics Shares Are Skyrocketing Today?

• The European Medicines Agency (EMA) has validated Aeglea BioTherapeutics Inc's (NASDAQ: AGLE) marketing application seeking approval for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D).

• Arginase deficiency is an inherited disorder that causes the amino acid arginine (a building block of proteins) and ammonia to accumulate gradually in the blood.

• Ammonia, formed when proteins are broken down in the body, is toxic if levels become too high.

• Related: Aeglea BioTherapeutics Shares Plummet Following Refusal To File Letter From FDA.

• Patients experience severe spasticity-related mobility limitations, seizures, developmental delay, intellectual disability, and early mortality.

• The application was submitted by Immedica Pharma AB, Aeglea's commercialization partner in Europe and the Middle East.

• The EMA has granted pegzilarginase orphan drug designation.

• Immedica's submission includes data from multiple clinical studies, including the PEACE Phase 3 study and its ongoing long-term extension, a Phase 1/2 trial, and an open-label extension study.

• Results showed that pegzilarginase could rapidly and sustainably lower arginine levels and improve mobility.

• In the PEACE study, most treatment-emergent adverse events were mild or moderate, and there were no discontinuations due to treatment-emergent adverse events.

• Price Action: AGLE shares are up 72.71% at $0.87 during the premarket session on the last check Friday.

See more from Benzinga

• Caribou's Blood Cancer Candidate Shows Response Rates Better Than Novartis,' This Analyst Writes

• Blueprint Medicines' Ayvakit 'Will Garner Approval' Despite Questions, This Analyst Says

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.